Why Ibex Stock Crushed it on Friday

Ibex reported fiscal Q4 revenue of just over $164 million, up nearly 12% year over year and above the roughly $153 million consensus estimate; adjusted EPS of $0.85 also beat the $0.79 forecast. The company recorded its sixth straight quarter of double-digit revenue growth, led by a 42% increase in healthcare technology, and shares rose nearly 7% on Friday. For fiscal 2027, management guided to $700 million-$715 million in revenue and $90 million-$94 million in adjusted EBITDA, with both low ends implying at least 9% growth.

Analysis

The key underwriting issue is not topline momentum but conversion: earnings growth materially lagged revenue growth, while the forward framework implies roughly stable EBITDA margins rather than operating leverage. That makes the post-results rerating vulnerable if wage inflation, offshore delivery costs, or client-transition expenses persist; the next two quarterly margin prints matter more than another revenue beat. Healthcare-tech exposure can support a premium growth multiple, but it also raises concentration risk if a small number of large platform clients slow implementations or bring customer-service workflows in-house.

IBEX's stated share-gain narrative creates a relative-value setup against scaled CX/BPO peers such as CNXC, TTEC and TASK, whose legacy voice-heavy books face greater pricing pressure and AI-disintermediation risk. The contrarian view is that generative AI may be lowering the value of labor-based customer engagement faster than IBEX can monetize higher-value acquisition and digital services; revenue growth without margin expansion would validate that concern over the next 1-3 months. Over 6-18 months, durable upside requires evidence that AI-enabled offerings lift revenue per agent and reduce delivery costs, not merely preserve client volumes.

The immediate move should not be chased without validating float, average daily dollar volume, and valuation versus EBITDA growth; smaller CX names can gap on limited liquidity and reverse when post-earnings demand fades. Thesis is falsified by a reduction in the current-year EBITDA outlook, adjusted EBITDA margin falling below the prior-year level for two consecutive quarters, or healthcare-tech growth decelerating sharply. A sustained margin inflection would instead justify multiple expansion and distinguish IBEX from structurally challenged outsourcing peers.

Key Decisions for Investors

• Do not chase the initial gap; place IBEX on a 1-3 month watch for a pullback or consolidation, contingent on confirming adequate liquidity and an EV/forward-EBITDA valuation discount or parity to CNXC and TASK despite superior organic growth.
• Conditional pair trade: long IBEX / short CNXC over the next two earnings cycles, sized beta-neutral, only if IBEX maintains or raises EBITDA guidance while CNXC shows further revenue or margin pressure. Target 10-15% relative outperformance; exit if IBEX's EBITDA margin declines year over year or CNXC guides to stabilization.
• Monitor quarterly revenue growth versus adjusted EBITDA growth as the primary catalyst. A second consecutive period of double-digit revenue growth with EBITDA growth catching up would support adding exposure; flat-to-down incremental margins despite growth is a stop signal.
• Avoid listed options unless open interest and spreads are verified; for a likely lower-liquidity name, cash equity with predefined position limits is preferable to paying elevated implied volatility after an earnings gap.